Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease

• Main Authors: Liang Chen (Author), Zhanjun Lu (Author), Dengfeng Kang (Author), Zhongsheng Feng (Author), Gengfeng Li (Author), Mingming Sun (Author), Zhanju Liu (Author), Wei Wu (Author), Leilei Fang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and Aims: Anti-tumor necrosis factor mAb (i.e., adalimumab, ADA) is currently used in the treatment of patients with Crohn's disease (CD). However, its regulation on fecal microbiota is still not fully understood.Methods: A retrospective analysis was conducted on 115 patients with CD...